US Patent

US9107912 — Methods for concomitant treatment of theophylline and febuxostat

Method of Use · Assigned to Takeda Pharmaceuticals USA Inc · Expires 2031-09-08 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating hyperuricemia in patients who also require theophylline treatment without causing theophylline toxicity.

USPTO Abstract

The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1346 — Uloric
U-1346 — Uloric

Patent Metadata

Patent number
US9107912
Jurisdiction
US
Classification
Method of Use
Expires
2031-09-08
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceuticals USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.